The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of ocular adverse events (AEs)
Timeframe: 60 months
Incidence of ocular serious adverse events (SAEs)
Timeframe: 60 months
Incidence of ocular adverse events (AEs) leading to discontinuation
Timeframe: 60 months
Incidence of adverse events (AEs)
Timeframe: 60 months
Incidence of serious adverse events (SAEs)
Timeframe: 60 months
Incidence of adverse events (AEs) leading to discontinuation
Timeframe: 60 months
Incidence of adverse events (AEs) leading to death
Timeframe: 60 months